TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Ascelia Pharma AB ( (SE:ACE) ).
Ascelia Pharma announced that Fenja Capital II A/S has requested the conversion of all outstanding convertibles, resulting in the issuance of 2,218,933 new ordinary shares. This conversion increases the total number of outstanding shares and slightly dilutes the existing shares by approximately 1.88%. The company’s cash runway is now extended into the second quarter of 2026, which may impact its financial stability and operational planning.
More about Ascelia Pharma AB
Ascelia Pharma is a biotech company specializing in orphan oncology treatments, focusing on developing and commercializing novel drugs to meet unmet medical needs. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm.
Average Trading Volume: 999,504
Technical Sentiment Signal: Buy
Current Market Cap: SEK573.2M
For an in-depth examination of ACE stock, go to TipRanks’ Overview page.